Cashu
Sanofi Acquires Dynavax Technologies for $2.2 Billion to Boost Immunotherapy Innovation
about 10 hours ago
Stocks
Health Care
dvax
Dynavax Technologies
NASDAQ: DVAX
+4.25 (+38.19%)
15.38
USD
At close at Dec 25, 17:35 UTC
Overview
Loading chart...
Key Stats
Market Cap
1.80B
Dividend Yield
0.00%
P/E Ratio
-41.56
EPS
0.21
Revenue
277.25M
Avg. Volume
7.85M
About
What does DVAX do?
Dynavax Technologies is a biopharmaceutical company based in Emeryville, California, specializing in vaccines and immuno-oncology therapeutics, including the HEPLISAV-B hepatitis B vaccine. The company is developing additional vaccines, including candidates for shingles and Tdap.
Join our newsletter to keep up to date with us!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.